Joe Reda

About

The immune system defends us, and sometimes it turns on us. I want to know whether that balance can be tipped on purpose.

The question took me from Miami to Chicago to New York, by way of protein engineering, computational biology, and a lot of mouse work.

I'm a postdoctoral researcher at NYU, working with Jeffrey Hubbell on proteins that use efferocytic pathways to induce tolerance to one antigen at a time, in autoimmune disease and in transplantation.

I write my own computational tools as I go, usually to make an analysis reproducible or to take a tedious step out of the week.

Education

Ph.D., Molecular Engineering

University of Chicago, Pritzker School of Molecular Engineering

Advisor: Jeffrey A. Hubbell

Dissertation: Recombinant Fusions of Antigen with Mediators of Efferocytosis Modulate Antigen-Specific Immune Responses

B.S., Biomedical Engineering, Summa Cum Laude

University of Miami

High School

Illinois Mathematics & Science Academy

Technical Expertise

Wet Lab

Protein Engineering Molecular Biology Spectral Flow (25-color) Mouse Models OT-I/OT-II Systems mRNA-LNP Gene Therapy

Computational

High-dimensional Flow Analysis FlowJo R / Bioconductor Python Data Visualization

I lead the single-cell multiome and spatial-transcriptomics analysis on a Colton Center for Autoimmunity grant.

AI-Augmented Workflow

I use LLM agents daily, mostly to build the tooling my experiments need and to manage observations and data analysis. I work with foundation models developed to predict small molecule binding to proteins, leveraging this to design novel research projects in immunomodulation.

LLMs & Agents HPC (Slurm) Foundation-model Application Reproducible Tooling
Tools I've built

Research Focus

My work rests on one hypothesis: that efferocytosis, the process by which phagocytes clear apoptotic cells, can be used to induce tolerance to a chosen antigen.

If a protein can engage those pathways while carrying the right antigen, autoimmune disease and transplant rejection might be treated without suppressing the whole immune system, as current therapies do.